From VEN/HMA combination design to venetoclax-resistance profiling and biomarker enrichment, xCellSense® assesses how your AML asset performs in primary patient cells.
Request a Quote
AML is genomically heterogeneous and increasingly combination-driven. Venetoclax/HMA backbones and emerging triplets require functional confirmation, and the post-venetoclax-failure population is growing — a setting in which genomics alone rarely predicts what will work.
1
Combination design
Sponsor asset ±venetoclax, HMA, and standard-of-care, with quantitative synergy matrices andranking.
2
Resistance profiling
Activity benchmarkingin venetoclax- and SOC-failure blasts.
3
Modality readouts
Antigen density anddegrader PD readouts for ADC, bispecific, and degrader programs.
4
Biomarker correlation
Genotype-to-responseassociation across myeloid drivers (e.g., FLT3, NPM1, IDH1/2, TP53).
Rational combination and dose selection, credible differentiation of relapsed/refractory cases, and sharper biomarker enrichment before Phase 1/2.
Key Deliverables
A scientist — not a sales desk — will scope a tailored AML study and return a design and timeline.
